Fully automated determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug testing.

[1]  L. Cucullo,et al.  A convenient UHPLC-MS/MS method for routine monitoring of plasma and brain levels of nicotine and cotinine as a tool to validate newly developed preclinical smoking model in mouse , 2017, BMC Neuroscience.

[2]  A. Van Schepdael,et al.  Quantitative mass spectrometry methods for pharmaceutical analysis , 2016, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[3]  J. Henion,et al.  Quantitative determination of opioids in whole blood using fully automated dried blood spot desorption coupled to on-line SPE-LC-MS/MS. , 2016, Drug testing and analysis.

[4]  M. Thevis,et al.  Dried blood spots (DBS) in doping controls: a complementary matrix for improved in- and out-of-competition sports drug testing strategies , 2015 .

[5]  C. Chiamulera,et al.  Acute effect of Snus on physical performance and perceived cognitive load on amateur footballers , 2015, Scandinavian journal of medicine & science in sports.

[6]  B. Chowdhry,et al.  Investigation of different approaches to incorporating internal standard in DBS quantitative bioanalytical workflows and their effect on nullifying hematocrit-based assay bias. , 2015, Analytical chemistry.

[7]  M. Thevis,et al.  Determination of Synacthen® in dried blood spots for doping control analysis using liquid chromatography tandem mass spectrometry , 2015, Analytical and Bioanalytical Chemistry.

[8]  Aurélien Thomas,et al.  New microfluidic-based sampling procedure for overcoming the hematocrit problem associated with dried blood spot analysis. , 2015, Analytical chemistry.

[9]  C. Guenancia,et al.  Smokeless tobacco, sport and the heart. , 2015, Archives of cardiovascular diseases.

[10]  W. Lambert,et al.  Current strategies for coping with the hematocrit problem in dried blood spot analysis. , 2014, Bioanalysis.

[11]  M. Thevis,et al.  Use of dried blood spots in doping control analysis of anabolic steroid esters. , 2014, Journal of pharmaceutical and biomedical analysis.

[12]  R. N. Rao.  Emerging liquid chromatography-mass spectrometry technologies improving dried blood spot analysis. , 2014, Expert review of proteomics.

[13]  M. Thevis,et al.  Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes. , 2014, Journal of pharmaceutical and biomedical analysis.

[14]  Donald H Chace,et al.  Microsample analyses via DBS: challenges and opportunities. , 2013, Bioanalysis.

[15]  B. Lindgren,et al.  Cotinine and trans 3′-hydroxycotinine in dried blood spots as biomarkers of tobacco exposure and nicotine metabolism , 2013, Journal of Exposure Science and Environmental Epidemiology.

[16]  E. Verheij,et al.  The effect of hematocrit on bioanalysis of DBS: results from the EBF DBS-microsampling consortium. , 2013, Bioanalysis.

[17]  P. Demirev.  Dried blood spots: analysis and applications. , 2013, Analytical chemistry.

[18]  D. Eichner,et al.  Quantification of insulin-like growth factor-1 in dried blood spots for detection of growth hormone abuse in sport , 2013, Analytical and Bioanalytical Chemistry.

[19]  M. Thevis,et al.  Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing , 2012, Analytical and Bioanalytical Chemistry.

[20]  M. Thevis,et al.  Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer , 2012, Analytical and Bioanalytical Chemistry.

[21]  Patrice Mangin,et al.  Direct analysis of dried blood spots coupled with mass spectrometry: concepts and biomedical applications , 2012, Analytical and Bioanalytical Chemistry.

[22]  M. Saugy,et al.  A one-year monitoring of nicotine use in sport: frontier between potential performance enhancement and addiction issues. , 2011, Forensic science international.

[23]  M. Thevis,et al.  Dried blood spots (DBS) for doping control analysis , 2011 .

[24]  E. Koster,et al.  Exploration of a new concept for automated dried blood spot analysis using flow-through desorption and online SPE-MS/MS. , 2011, Bioanalysis.

[25]  Erik A. Meulman,et al.  Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. , 2011, Biomedical chromatography : BMC.

[26]  P. Timmerman,et al.  EBF recommendation on the validation of bioanalytical methods for dried blood spots. , 2011, Bioanalysis.

[27]  H. Pandya,et al.  Dexamethasone quantification in dried blood spot samples using LC-MS: The potential for application to neonatal pharmacokinetic studies. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[28]  M. Saugy,et al.  Determination of nicotine and nicotine metabolites in urine by hydrophilic interaction chromatography-tandem mass spectrometry: Potential use of smokeless tobacco products by ice hockey players. , 2010, Journal of chromatography. A.

[29]  H. Pandya,et al.  Facilitating pharmacokinetic studies in children: a new use of dried blood spots , 2010, Archives of Disease in Childhood.

[30]  M. Rowland,et al.  Use of Dried Blood Spots in Drug Development: Pharmacokinetic Considerations , 2010, The AAPS Journal.

[31]  Wenkui Li,et al.  Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. , 2010, Biomedical chromatography : BMC.

[32]  R. Lang-Roth,et al.  Allgemeine und spezielle Pharmakologie und Toxikologie , 2009 .

[33]  T. Fukami,et al.  CYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONS , 2005, Drug Metabolism and Disposition.

[34]  J. Henningfield,et al.  Pharmacokinetics and pharmacodynamics of moist snuff in humans , 1999, Tobacco control.

[35]  N. Benowitz,et al.  Systemic Absorption and Effects of Nicotine From Smokeless Tobacco , 1997, Advances in dental research.

[36]  G. Löffler,et al.  Biochemie und Pathobiochemie , 1997 .

[37]  J. Henningfield,et al.  Estimation of available nicotine content of six smokeless tobacco products , 1995 .

[38]  J. Wahren,et al.  New methods for probing the disposition of nicotine in humans , 1993 .

[39]  N. Benowitz,et al.  Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum , 1988, Clinical pharmacology and therapeutics.

[40]  R. Guthrie,et al.  A SIMPLE PHENYLALANINE METHOD FOR DETECTING PHENYLKETONURIA IN LARGE POPULATIONS OF NEWBORN INFANTS. , 1963, Pediatrics.